Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma



[
Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma
[og_img]
https://www.investing.com/news/press-releases/junshi-biosciences-announces-approval-of-snda-for-toripalimab-in-combination-with-bevacizumab-for-1stline-treatment-of-advanced-hepatocellular-carcinoma-93CH-3943493


Investing.com

Latest articles

spot_imgspot_img

Related articles

spot_imgspot_img